

## DNA Methylation and Its Effect on Various Cancers: An Overview

Sabitha Vadakedath<sup>1</sup> and Venkataramana Kandi<sup>2\*</sup>

<sup>1</sup>Department of Biochemistry, Chalmeda Anandrao Institute of Medical sciences, Karimnagar, India

<sup>2</sup>Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, India

\*Corresponding author: Venkataramana kandi, Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, India, Tel: 0878 221 6380; E-mail: ramana\_200221@rediffmail.com

Rec date: Feb 28, 2016, Acc date: Mar 24, 2016, Pub date: Mar 26, 2016

Copyright: ©2016 Vadakedath S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

DNA methylation is a normal phenomenon which helps in gene expression, cell differentiation and is an inheritable process. Altered DNA methylation patterns in coding strands lead to epigenetic modification. These epigenetic changes enhances DNA adduct formation, somatic mutations and oncogene activation. During silencing of tumor suppressor genes, various genes/proteins involved in signaling pathways gets disturbed. These changes are reversible but if mutations occur they become irreversible. Hence early detection of these genes/proteins involved in epigenetic alterations may help in decreasing the associated changes in the body.

**Keywords:** DNA methylation; Epigenetic modifications; Oncogene activation; Altered methylated pattern

### Introduction

The process of covalent addition of methyl group to cytosine residue of DNA molecule is called DNA methylation. The methyl group adds to the 5' carbon of cytosine ring forming 5-methyl cytosine as shown in Figure 1.

These methyl groups project into major groove of DNA, which in turn inhibit transcription [1]. Thus, methylation of DNA occurs mostly at CG sites as shown in Figure 2.

The stretch of DNA where there is frequent appearance of methyl cytosine is called CPG islands. These islands are mostly seen near promoter region of transcription (initiation site) thereby inhibiting the process of transcription [2]. DNA methylation of non-coding region of DNA helps to maintain transcriptional silencing whereas in coding region of DNA it leads to an epigenetic modification. Epigenetics is a heritable change in gene expression without a change in nucleotide sequence. These epigenetic modifications include spontaneous deamination, enhanced binding of DNA to carcinogens and increased ultraviolet absorption by DNA.

This in turn enhances the rate of mutations and DNA adducts formation and gene inactivation [3,4]. Methylation of DNA is catalysed by DNA methyl transferase in which methyl donor is S-adenosyl methionine (SAM). This methylation of DNA not only causes change in transcriptional activity but also leads to change in chromatin structure in promoter region of the gene [5]. This paper attempts to review genetic changes attributed to abnormalities in DNA methylation which in turn activate tumorigenic potential of cells further leading to cancer.

### Changes in chromatin structure on DNA methylation

DNA methylation alters histones of chromatin structure by activating histone deacetylase (HDA). HAD enzyme removes acetyl group from histone which allows stronger interaction between DNA

backbone and histones. This induces a tight chromatin structure which becomes inaccessible to transcriptional machinery. Thus, DNA methylation alters chromatin configuration from open to closed form, silencing gene expression [6].






Figure 1: The reaction showing methylation of cytosine residues.

The amino terminal tails of histone protrude from nucleosome which can undergo post-translational modifications (like acetylation, ubiquitination, phosphorylation etc.). This in turn, affects the repressive/permissive behavior of transcription of gene [7]. The open chain histone conformation shows permissive nature whereas closed conformation represses the process of transcription [8]. Thus, DNA methylation influences histone modifications as shown in Figure 3.



Thus, hypermethylation on DNA, causes silencing of retroviral endogenous elements leading to enhanced somatic mutations and oncogene activation/inactivation of tumor suppressor genes.

### Epigenetic alteration induced mutation


DNA methylation silencing of tumor suppressor genes leads to change in nucleosome positioning at the transcriptional start site as well as loss of histone acetylation (HA). The normal histone acetylation can be restored by the use of HA inhibitors which leads to anti-tumorigenic effects revealing the fact that HA inhibitors may reactivate the silenced tumor suppressor genes. Reactivation of these genes by DNA methyl transferase inhibitors as well as HA inhibitors contribute to loss of nucleosome from promoter site of transcription [13,14].

### Ovarian Cancer

Ovarian cancer is the most lethal cancer of female genital tract. Its detection gets delayed as it shows few symptoms during its course [15]. A large number of genes get hypermethylated and silenced in ovarian cancer [16]. The most altered genes include CDKN2A, which is a cell cycle control gene silenced by promoter methylation and is a predictive marker for ovarian cancer [17,18]. Previous research studies have indicated that CDH13, a gene coding for cell adherence protein (H-Cadherin) is another one which frequently causes hypermethylation and can be responsible for ovarian cancer [19,20]. Previous studies have also noted that RASSF1, a tumor suppressor gene does transcriptional silencing by incomplete promoter methylation [21,22].

### Breast Cancer

Breast cancer is a heterogeneous disease, both biologically and clinically. These cancers are subdivided into basal-like, ERBB2+, luminal B and luminal A [23,24]. These subtypes showed different methylation patterns. Basal-like tumors showed least methylation and luminal B displayed highest methylation pattern [25]. It was observed



### Role of DNA methylation in cancer-a generalized view

In a normal healthy individual DNA methylation ensures proper gene expression, differentiation during embryonic stage, and to transmit the methylated patterns from parent to offspring in one of the allele of the gene representing germ line transmission. The process of transmission of methylated patterns from one generation to next is called imprinting. Loss of this imprinting leads to Prader-Willi syndrome, Angelman's syndrome etc. The altered DNA methylation pattern in somatic tissue leads to cancer. The mismatched DNA methylated patterns are majorly seen in promoter region of the gene [9-12]. DNA methylation and its role in generation of cancer are shown in Figure 4.

that expression five biomarkers varied between basal-like and other subtypes. In basal-like tumors NPY, FGF2, HS3ST2, RASSF1 and Let-7a showed lack of methylation [26].

## Endometrial Cancer

It is seventh most commonly occurring cancers in women worldwide. The underlying reason for development of endometrial cancer is not clear but epigenetic modification like DNA hypermethylation provides complete explanation for development of endometrial cancer. This hypermethylated DNA in turn causes breakdown of DNA, mismatch repair mechanism causing a change in expression of genes like human Mut L homolog 1 (hMLH1) and human Mut S homolog 2(hMLH2) [27]. DNA hypermethylation in turn down regulates expression of genes like APC, E cadherin, CHFR, CASP8 [28-30]. Research has observed that APC (Adenopolyposis coli) hypermethylation which is not found in normal endometrial hyperplasia was seen in endometrial cancer [31]. CHFR (Checkpoint with FHA and RING) hypermethylation also was noted to cause endometrial cancer [32]. Sprouty 2 (SPRY 2) promotes growth of glandular structures, acts as antagonist to regulator of MAPK receptor tyrosine kinase and its action is in accordance to menstrual cycle. Extreme low expression of these genes was noted in invasive and endometrial cancer [33-35]. RASSF1A gene regulates cell proliferation and apoptosis by regulatory MAPK pathway and its low expression indicates advanced stages of endometrial cancer [36]. GPR 54 is a suppressor gene for cancer metastasis and its reduced expression leads to endometrial cancer [37]. Low expression of CDH1 gene could be linked to generation of endometrial cancer [38]. X-linked Ribosomal S6 kinase (RPS6KA6)/(RSK 4) was noted to inhibit transcriptional activity of tyrosine kinase receptor. This is associated with activation of FGFR2/RAS/ERK signal pathway and acts as a tumor suppressor. Reduced activity of CDH1 gene is therefore seen in endometrial cancer [39]. EPCAM (Epithelial cell adhesion molecule), is an intercellular adhesion molecule that prevents metastasis. Mutation of gene coding for this molecule was observed to cause endometrial cancer [40,41].

## Lung Cancer

It is one of the most prevalent cancers and leading cause of cancer deaths in the world. Several tumor suppressor genes get methylated and become inactive and could be responsible for genesis of lung cancer. RAR Beta (Retinoic acid receptor beta -2) gene involved in mediating growth control responses was observed to become defective in both primary and non-small cell lung cancers (NSCLCS) and heavy smokers [42-44]. Previous research has noted that RASSF1A gene activity was lost in lung cancer [45]. Other recent studies have indicated that abnormality in FHIT (Fragile Histidine triad) gene could be linked to lung cancer [46,47]. Research studies in the past have noted that Cadherins are a family of cell surface glycoproteins responsible for cell recognition and adhesion and that defect in CDH 13 could be responsible for lung carcinoma [48,49]. A previous study has noted that APC (Adematous polyposis coli) is a gene which gets methylated frequently in lung cancer [50]. Another study has found that P16 gets methylated and binds to cyclin dependent protein kinase and inhibits binding to cyclin D1 which may be linked to lung cancer [51].

## Stomach Cancer

Gastric cancer remains a common cancer type in humans. Various factors like smoking, diet and Helicobacter pylori infection could contribute to gastric cancer. Research has noted that hypermethylation and silencing of E (epithelial) cadherin, a tumor suppressor gene is frequently observed in gastric carcinomas [52]. Silenced E cadherin gene in turn was associated with development of Epstein-Barr virus (EBV) associated gastric carcinoma [53]. Thus, DNA methylation at promoter region of tumor suppressor gene alters cell cycle, growth and motility, as well as adhesion molecules by silencing expressions of p16, p15, DAPK, RUNX3, MLH. Loss of oncogene promoter region leads to over expression genes such as S100A4, VEGF-C, PAR2, SNCG and MAGE-A1-3 in gastric cancer [54,55].

## Liver Cancer

Hepatocellular carcinoma/Liver cancer is one of the most common cancer worldwide due to its poor prognosis. Hypermethylation of genes like RASSF1A, CDKN2A, CCNA1, P16 were identified in cancer tissue of liver compared to healthy tissue [56]. Similarly, KLK10 and OXGR 1 genes were also noted to induce hypermethylation. KLK10 hypermethylation was found to be associated with Hepatitis C virus (HCV) infection and liver cirrhosis [57]. Hypomethylation of AKR1B10, CENDH, MMP9, MMP12, PAGE 4, S100A5, MMP2 and NUPR1 was also noted in liver cancer [58]. The etiological factors like hepatitis B viral infection (HBV), alcohol consumption can alter DNA methylation patterns leading to epigenetic changes and tumorigenesis.

## Colon Cancer

Colon cancer is the third most diagnosed cancer in both men and women. The genes MGMT, hMLH1, P16, MINT1, MINT31, COX2, cyclin A1, CDX1, RAR-b, MYOD1, P15, CDH13, CXX1, P73 and WT1 showed altered methylation pattern and could be associated with colon cancer [59]. Previous studies have also observed that CDH5 gene inactivation can lead to changes in chromatin structure and that genetic disruption of APC, RAS and P53 pathways could initiate colon cancer [60,61]. DNA methylation pattern and epigenetic modification can be reverted but if there is mutation of genes in this process it becomes an irreversible change.

## Brain Tumor

Gliomas or brain tumors are the tumors of central nervous system (CNS) with wide spectrum of different tumor types. The genes CDKN2B, MYOD1, CDH1, TIMP3, THBS1, PTGS2, CALCA showed methylation changes and these genes had a role in cell cycle, growth regulation, cell differentiation, angiogenesis and tumor metastasis [62-64].

## Skin Cancer

Globally, skin cancer is the most frequent form of cancer responsible for more than 40% of cases. In skin cancer, methylation of E cadherin prevents cell adhesiveness. Studies in the past have observed changes in HaCa4 cells in later stages of cancer. It was also noted that hypermethylation of E cadherin demethylates snail protein, recruits histone deacetylase activity and inhibits methyl transferase enzyme [65-67]. The target genes involved in gene silencing and primary skin cancer includes IGFBP3, CMKAR4, PRDX1, CSRP2

[68-70]. Thus, tumor suppressor gene inactivation leads to activation of cascade of events to skin cancer.

## Challenges and Future Perspective

Further studies concentrating on altered DNA methylation pattern may be crucial in early detection of tumorigenic activity and also could help in designing drugs for treating human diseases attributed to altered DNA methylation. DNA methylation biomarkers should be considered as a corner stone in the diagnosis of cancers. Studies in the future should concentrate on the development and validation of potential DNA methylation biomarkers. DNA methylation abnormalities could also be linked to other diseases that include and not limited to developmental disorders leading to neurological defects, cardiovascular diseases, endocrinal disorders, nutrition and exposure to environmental toxins and stress conditions. Markers of epigenetic changes although are currently available, they require extensive and large scale validation studies before being used either for the diagnosis or prevention.

## Conclusion

The process of DNA methylation is a natural phenomenon to ensure proper growth, cell adhesion, and genetic transmission. Abnormal or altered DNA methylation leads to silencing of tumor suppressor genes, thus promotes enhanced multiplication of cells, extensive invasive nature to the cell and in turn cells are transformed to cancerous cells. During its transformation to malignant cells a large number of proteins involved in different signaling pathways are altered or sometimes become mutated (irreversible). Hence early estimation of these protein levels in blood may help to know the altered DNA methylation pattern and thus we can minimize the risk of cancer due to this abnormal pattern of DNA methylation.

## References

1. Bird A (2002) DNA methylation patterns and epigenetic memory. *Genes Dev* 16: 6-21.
2. Herman JG, Baylin SB (2003) Genes silencing in cancer in association with promoter hypermethylation. *N Engl J Med* 349: 2042-2054.
3. Jones PA And Baylin SB (2002) The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 3: 415-428.
4. Craig JM, Wong NC Epigenetics : A Reference manual. Caister Academic press. ISBN 978-1-904455-88-2.
5. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyl transferase Dnmt 3a & Dnmt 3b are essential for denovo methylation & mammalian development. *Cell* 99: 247-257.
6. Bird AP, Wolffe AP (1999) Methylation-induced repression-belts, braces and chromatin. *Cell* 99: 451-454.
7. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al. (2005) Loss of acetylation at Lys 16 and trimethylation at Lys 20 of histone H4 is a common hallmark of human cancer. *Nat Genet* 37: 391-400.
8. Wen B, Wu H, Shinkai Y, Irizarry RA, Feinberg AP (2009) Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. *Nat Genet* 41: 246-250.
9. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5' CPG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS 1 in human cancers. *Nat Med* 1: 686-692.
10. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, et al. (2001) Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. *Oncogene* 20: 1765-1770.
11. Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, et al. (2006) The methylation status and protein expression of CDH1, P16 (INK4A), and fragile histidine triad in non small cell lung carcinoma : epigenetic silencing, clinical features, and prognostic significance. *Cancer* 106: 2190-2199.
12. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, et al. (2003) Induction of tumors in mice by genomic hypomethylation. *Science* 300: 489-492.
13. Lin JC, Jeong S, Liang G, Takai D, Fatemi M, et al. (2007) Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. *Cancer Cell* 12: 432-444.
14. Carew JS, Giles FJ, Nawrocki ST (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. *Cancer Lett* 269: 7-17.
15. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2008) Cancer statistics. *CA cancer J Clin* 57: 43-66.
16. Barton CA, Hacker NF, Clark SJ, O'Brien PM (2008) DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. *Gynecol Oncol* 109: 129-139.
17. Lee YH, Heo JH, Kim TH, Kang H, Kim G, et al. (2011) Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. *Int J Gynecol Pathol* 30: 205-217.
18. Ozdemir F, Altinisk J, karateke A, Coksuer H, Buyru N, et al. (2012)Methylation of tumor suppressor genes in ovarian cancer. *Exp Ther Med* 4: 1092-1096.
19. Kawakami M, Staub J, Cliby W, Hartman L, Smith DI, et al. (1999) Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. *Int J Oncol* 15: 715-720.
20. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, et al. (2005) Promoter hypermethylation profile of ovarian epithelial neoplasms. *Clin cancer Res* 11: 5365-5369.
21. Dammann R, Schagdarsurengin U, Seidal C, Strunnikova M, et al. (2009) The tumor suppressor RASSF1A in human carcinogenesis : an update. *Histol Histopathol* 27: 307-312.
22. Buyru N, Altinisk J, Ozdemir F, Demokan S, Dalay N (2009) Methylation profiles in breast cancer. *Cancer Invest* 27:307-312.
23. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumors. *Nature* 406: 747-752.
24. Sorlie T, Perou CM, Tibshirani R, Aas T, Geislers, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci* 98: 10869-10874.
25. Terada K, Okochi-Takada E, Akashi-Tanaka S, Miyamoto K, TAniyama K, et al. (2009) Association between frequent CpG island methylation and HER2 amplification in human breast cancers. *Carcinogenesis* 30: 466-471.
26. Bediaga NG, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, et al. (2010) DNA methylation epigenotypes in breast cancer molecular subtypes. *Breast cancer Research*.
27. Banno K, Kisu I, Yanokura M, Masuda K, Kobayashi Y, et al. (2012) Endometrial cancer and hypermethylation: Regulation of DNA and micro RNA by epigenetics. *Biochem Research International*.
28. Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, et al. (2009) Epigenetic DNA hypermethylation: clinical applicants in endometrial cancer. *Oncology Reports* 22: 967-972.
29. Wajed SA, Laird PW, Demeester TR(2001) DNA methylation: an alternative pathway to cancer. *Ann surg* 234: 10-20.
30. Esteller M (2008) Epigenetics in cancer. *N Eng J Med* 358: 1148-1159.
31. Ignatov A, Bischoff J, Ignatov T, Schwarzenau C, Krebs T, et al. (2010) APC promoter hypermethylation is an early event in endometrial tumorigenesis. *Cancer Sci* 101: 321-327.
32. Wang X, Yang Y, Xu C, Xiao L, Shen H, et al. (2011) CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel. *Int J Gynecol cancer* 21: 996-1003.
33. Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, et al. (2004) The Ras/mitogen-activated protein kinase pathway inhibitor and likely tumor

- suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. *Cancer Res* 64: 6127-6136.
34. Sutterlüty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, et al. (2007) Down regulation of sprouty 2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and independent mechanisms. *Mol cancer Res* 5: 509-520.
35. Fong CW, Chua MS, McKie AB, Ling SH, Mason V, et al. (2006) Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down regulated in hepatocellular carcinoma. *Cancer Res* 66: 2048-2058.
36. Pallarés J, Velasco A, Eritja N, Santacana M, Dolcet X, et al. (2008) Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. *Mod Pathol* 21: 691-699.
37. Kang HS, Baba T, Mandai M, Matsumura N, Hamanishi J, et al. (2011) GPR54 is a target for suppression of metastasis in endometrial cancer. *Mol cancer Ther* 10: 580-590.
38. Yi TZ, Guo J, Zhou L, Chen X, Mi RR, et al. (2011) Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma. *Cancer Invest* 29: 86-92.
39. Dewdney SB, Rimel BJ, Thaker PH, Thompson DM Jr., Schmidt A, et al. (2011) Aberrant methylation of X-linked ribosomal S6 kinase RPS6KA6(RSK 4) in endometrial cancers. *Clin cancer Res* 17: 2120-2129.
40. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, et al. (2010) EPCAM in carcinogenesis: the good, the bad or the ugly. *Carcinogenesis* 31: 1913-1921.
41. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, et al. (2009) Heritable somatic methylation and inactivation of MSH2 in families with lynch syndrome due to deletion of 3' exons of TACSTD1. *Nat Genet* 41: 112-117.
42. Gebert JE, Moghal N, Frangioni JV, Sugarbaker DJ, Neel BG, et al. (1991) High frequency of retinoic acid receptor beta abnormalities in human lung cancer. *Oncogene* 6: 1859-1868.
43. Geradts J, Chen JY, Russell EK, Yankaskas JR, Nieves L, et al. (1993) Human lung cancer cell exhibit resistance to retinoic acid treatment. *Cell Growth Differ* 4: 799-809.
44. Lu XP, Fanjul A, Picard N, Pfahl M, Rungta D, et al. (1997) Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells *in vivo*. *Nat Med* 3: 686-690.
45. Dammann R, Li C, Yoon JH, Chin PL, Bates S, et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. *Nat Genet* 25: 315-319.
46. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, et al. (1996) The FHIT gene 3p1.2 is abnormal in lung cancer. *Cell* 85: 17-26.
47. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, et al. (1997) The FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. *Cancer Res* 57: 2256-2267.
48. Toyooka KO, Toyooka S, Virmani AK (2001) Loss of expression and aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. *Clin Cancer Res* 7: 1998-2004.
49. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, et al. (2001) Loss of expression and aberrant methylation of CDH13 (H-cadherin) gene in breast and lung carcinomas. *Cancer Res* 61: 4556-4560.
50. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, et al. (2001) Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. *Clin Cancer Res* 7: 1998-2004.
51. Sheer CJ (1996) Cancer cell cycles. *Science*. 274: 1672-1677.
52. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, et al. (2000) E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. *J Natl Cancer Inst* 92: 569-573.
53. Sudo M, Chong JM, Sakuma K, Ushiku T, Uozaki H, et al. (2004) Promoter methylation of E-cadherin and its abnormal expression in Epstein-Barr-Virus associated gastric carcinoma. *Int J Cancer* 109: 194-199.
54. Hu SL, Kong XY, Cheng ZD, Sun YB, Shen G, et al. (2010) Promoter methylation of P16, RUN X3, DAPK and CHFR genes is frequent in gastric carcinoma. *Tumori*. 96: 726-733.
55. Li Y, Zhang KL, Sun Y, Yang Y, Chen XY, et al. (2008) Frequent S100A4 expression with unique splicing pattern in gastric cancers. A hypomethylation event paralleled with E-cadherin reduction and Wnt activation. *Transl Oncol* 1: 165-176.
56. Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, et al. (2008) Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. *Carcinogenesis* 29: 1901-1910.
57. Lu CY, Hsieh SY, Lu YJ, Wu CS, Chen LC, et al. (2009) Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma. *Genes chromosomes cancer* 48: 1057-1068.
58. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, et al. (2011) Definition of the landscape of promoter DNA hypomethylation in liver cancer. *Cancer Res* 71: 5891-5903.
59. Xu XL, Yu J, Zhang HY, Sun MH, Gu J, et al. (2004) Methylation profile of promoter CpG islands of 31 genes that may contribute to colorectal tumorigenesis. *World J Gastroenterol* 10: 3441-3454.
60. Mulero-Navarro S, Esteller M (2008) Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. *Epigenetics* 3: 210-215.
61. Michor F, Iwasa Y, Lengauer C, Nowak MA (2005) Dynamics of colorectal cancer. *Semin cancer Biol* 15: 484-493.
62. Herman JG, Jen J, Merlo A, Baylin SB (1996) Hypermethylation associated inactivation indicates a tumor suppressor role for P15INK4B. *Cancer Res* 56: 722-727.
63. Holland EC (2001) Gliomagenesis: genetic alterations and mouse models. *Nat Rev Genet* 2: 120-129.
64. Costello JE, Berger MS, Huang HS, Cavenee WK (1996) Silencing of P16/CDKN2 expression in human gliomas by methylation and chromatin condensation. *Cancer Res* 56: 2405-2410.
65. Navarro P, Gomez M, Pizarro A, Gamallo C, Quintanilla M, et al. (1991) A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. *J Cell Biol* 115: 517-533.
66. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat Cell Biol* 2: 76-83.
67. Manerich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V, et al. (2002) L-cys peroxidase overexpression protects cells against phospholipids peroxidation-mediated membrane damage. *Proc Natl Acad Sci USA* 99: 11599-115604.
68. Baxter RC (2001) Signaling pathways involved in antiproliferative effects of IGFBP-3: a review. *Mol Pathol* 54: 145-148.
69. Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, et al. (2002) Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. *Cancer Res* 62: 7328-7334.
70. Weiskirchen R, Günther K (2003) The CRP/MLP/TLP family of LIM domain proteins: acting by connecting. *Bioessays* 25: 152-162.